Cargando…
Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
Autores principales: | Stockmann, Julia, Verberk, Inge M. W., Timmesfeld, Nina, Denz, Robin, Budde, Brian, Lange-Leifhelm, Julia, Scheltens, Philip, van der Flier, Wiesje M., Nabers, Andreas, Teunissen, Charlotte E., Gerwert, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809829/ https://www.ncbi.nlm.nih.gov/pubmed/33451318 http://dx.doi.org/10.1186/s13195-021-00770-2 |
Ejemplares similares
-
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2020) -
Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer’s disease
por: Stocker, Hannah, et al.
Publicado: (2021) -
Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022) -
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018) -
Aβ misfolding in blood plasma is inversely associated with body mass index even in middle adulthood
por: Möllers, Tobias, et al.
Publicado: (2021)